Reaping the spoils of CGT’s golden age

While history notes that pirates have terrorized the seas for thousands of years — and still operate today — piracy peaked from 1650-1730. It was during this era of heightened activity, known as the ‘golden age of piracy,’ that sea-robbers captured public imagination and shaped the way pirates have been portrayed ever since.

Pirates, however, were more than just romanticized tropes. They posed serious threats to safety and commerce — attacking ships, stealing cargo, holding crews for ransom, and at times seizing entire vessels. These disruptions made seafaring perilous and jeopardized the economic stability of nations dependent on maritime trade.

That golden age eventually forced sailors, merchants, and governments to adapt. Survival at sea no longer depended on speed or firepower alone, but on careful planning, cross-border cooperation, and the adoption of new technologies. In many ways, today’s cell and gene therapy sector finds itself in a similar golden era — one defined by extraordinary opportunity, but also by heightened risk, rising costs, and increasingly complex paths to market.

Just as sailors learned to carefully chart routes to avoid pirate-infested waters — even if it meant the trip took significantly longer — CGT developers can no longer focus solely on speeding towards clinical milestones. The full journey, from early development through commercialization, must be plotted from the onset. Investing resources upfront to optimize manufacturing, regulatory strategy and scalability may add time, but it ultimately reduces risk, minimizes regulatory delays, and increases the likelihood of safe arrival to market.

Sailors also learned that traveling alone through dangerous waters was a losing strategy. Multi-vessel convoys and multinational naval coalitions enabled the sharing of intelligence, resources, and protection — an approach still used today to combat modern piracy. The Combined Maritime Forces, formed in 2002, now unites 47 nations to safeguard critical shipping lanes.

Similarly, CGT players are increasingly looking beyond borders for mutually beneficial partnerships. Whether sourcing early human data and novel assets from China or making bolt-on investments in established biotech hubs such as Switzerland, collaboration has become an all-hands-on-deck imperative for controlling costs and accelerating progress.

The tools of maritime defense have evolved as well. Where sailors once relied on brute force, modern anti-piracy efforts now deploy AI-powered surveillance, drones, and real-time analytics to detect threats before they materialize. The CGT industry is undergoing a comparable shift, with significant investment flowing into robotic, fully digitalized manufacturing platforms and automation — technologies that are already proving their value in scalability, efficiency, and reliability.

As CGT developers navigate increasingly treacherous waters, success will depend on more than shiny science. We are living in the golden age of cell and gene therapy — but the spoils will go to those who chart a deliberate course, choose the right partners, and translate breakthrough science into sustainable commercial reality.